Eli Cash vs Total Current Liabilities Analysis
LLY Stock | USD 807.43 1.02 0.13% |
Eli Lilly financial indicator trend analysis is much more than just examining Eli Lilly latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eli Lilly is a good investment. Please check the relationship between Eli Lilly Cash and its Total Current Liabilities accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Cash vs Total Current Liabilities
Cash vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eli Lilly Cash account and Total Current Liabilities. At this time, the significance of the direction appears to have no relationship.
The correlation between Eli Lilly's Cash and Total Current Liabilities is 0.0. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Eli Lilly and, assuming nothing else is changed. The correlation between historical values of Eli Lilly's Cash and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Eli Lilly and are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Cash i.e., Eli Lilly's Cash and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | 0.0 |
Relationship Direction | Flat |
Relationship Strength | Insignificant |
Cash
Cash refers to the most liquid asset of Eli Lilly, which is listed under current asset account on Eli Lilly and balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Eli Lilly customers. The amounts must be unrestricted with restricted cash listed in a different Eli Lilly account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Total Current Liabilities
Total Current Liabilities is an item on Eli Lilly balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Eli Lilly and are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Eli Lilly's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eli Lilly current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, Eli Lilly's Discontinued Operations is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.32 in 2024, whereas Selling General Administrative is likely to drop slightly above 5.7 B in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 21.0B | 21.9B | 27.5B | 28.9B | Total Revenue | 28.3B | 28.5B | 34.1B | 35.8B |
Eli Lilly fundamental ratios Correlations
Click cells to compare fundamentals
Eli Lilly Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eli Lilly fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 39.3B | 46.6B | 48.8B | 49.5B | 64.0B | 67.2B | |
Short Long Term Debt Total | 15.8B | 16.6B | 16.9B | 16.2B | 25.2B | 26.5B | |
Total Current Liabilities | 11.8B | 12.5B | 15.1B | 17.1B | 27.3B | 28.7B | |
Total Stockholder Equity | 2.6B | 5.6B | 9.0B | 10.6B | 10.8B | 9.0B | |
Property Plant And Equipment Net | 8.4B | 8.7B | 9.0B | 10.1B | 12.9B | 6.8B | |
Net Debt | 13.5B | 12.9B | 13.1B | 14.2B | 22.4B | 23.5B | |
Retained Earnings | 4.9B | 7.8B | 9.0B | 10.0B | 10.3B | 9.5B | |
Cash | 2.3B | 3.7B | 3.8B | 2.1B | 2.8B | 3.1B | |
Non Current Assets Total | 25.6B | 29.2B | 30.4B | 31.5B | 38.3B | 40.2B | |
Non Currrent Assets Other | 2.3B | 3.5B | 4.1B | 4.3B | 5.0B | 2.9B | |
Cash And Short Term Investments | 2.4B | 3.7B | 3.9B | 2.2B | 2.9B | 3.7B | |
Net Receivables | 5.5B | 6.9B | 8.1B | 8.6B | 11.3B | 11.9B | |
Common Stock Shares Outstanding | 935.7M | 912.5M | 911.7M | 904.6M | 903.3M | 868.4M | |
Liabilities And Stockholders Equity | 39.3B | 46.6B | 48.8B | 49.5B | 64.0B | 67.2B | |
Non Current Liabilities Total | 24.8B | 28.3B | 24.6B | 21.6B | 25.8B | 27.1B | |
Inventory | 3.2B | 4.0B | 3.9B | 4.3B | 5.8B | 6.1B | |
Other Current Assets | 2.5B | 2.9B | 2.5B | 3.0B | 149.5M | 142.0M | |
Other Stockholder Equity | 3.6B | 3.7B | 3.8B | 3.9B | 4.2B | 2.3B | |
Total Liab | 36.6B | 40.8B | 39.7B | 38.7B | 53.1B | 55.8B | |
Total Current Assets | 13.7B | 17.5B | 18.5B | 18.0B | 25.7B | 27.0B | |
Intangible Assets | 6.6B | 7.5B | 7.7B | 7.2B | 6.9B | 7.3B | |
Other Current Liab | 2.2B | 2.8B | 3.0B | 13.7B | 3.3B | 3.7B | |
Short Term Debt | 1.5B | 8.7M | 1.5B | 1.5B | 6.9B | 7.2B | |
Accounts Payable | 1.4B | 1.6B | 1.7B | 1.9B | 2.6B | 2.7B | |
Property Plant And Equipment Gross | 8.4B | 8.7B | 19.0B | 20.4B | 24.0B | 25.2B | |
Accumulated Other Comprehensive Income | (6.5B) | (6.5B) | (4.3B) | (3.8B) | (4.3B) | (4.5B) | |
Common Stock Total Equity | 661M | 598.8M | 598.2M | 594.1M | 534.7M | 494.1M | |
Short Term Investments | 101M | 24.2M | 90.1M | 144.8M | 109.1M | 103.6M | |
Capital Stock | 598.8M | 598.2M | 596.3M | 594.1M | 593.6M | 544.7M | |
Common Stock | 598.8M | 598.2M | 596.3M | 594.1M | 593.6M | 544.7M | |
Other Liab | 10.5B | 11.0B | 8.7B | 6.1B | 7.0B | 5.5B | |
Other Assets | 4.7B | 9.3B | 6.4B | 7.1B | 8.2B | 4.2B | |
Long Term Debt | 13.8B | 16.6B | 15.3B | 14.7B | 18.3B | 19.2B | |
Treasury Stock | (60.8M) | (55.7M) | (52.7M) | (50.5M) | (44.2M) | (46.4M) | |
Property Plant Equipment | 7.9B | 8.7B | 9.0B | 10.1B | 11.7B | 8.5B | |
Good Will | 3.7B | 3.8B | 3.9B | 4.1B | 4.9B | 2.9B | |
Current Deferred Revenue | 6.7B | 8.1B | 8.8B | 14.5B | 16.7B | 17.5B | |
Noncontrolling Interest In Consolidated Entity | 92.2M | 183.6M | 175.6M | 125.6M | 91.8M | 141.7M | |
Retained Earnings Total Equity | 13.9B | 11.4B | 4.9B | 10.0B | 11.5B | 10.8B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
GM | General Motors | |
CRM | Salesforce |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.664 | Dividend Share 4.69 | Earnings Share 6.78 | Revenue Per Share 39.919 | Quarterly Revenue Growth 0.26 |
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.